Business Context and Reporting Period
This Form 6-K filing by BiondVax Pharmaceuticals Ltd. (the "Company") covers the month of August 2015, specifically reporting on an immediate disclosure published on the Tel-Aviv Stock Exchange on July 31, 2015. The Company is a public entity trading on the Tel Aviv Stock Exchange (TASE) and the Nasdaq Capital Market (via American Depositary Shares). The filing details the grant of unregistered stock options to employees and officers under the Company's 2005 Option Plan.
Key Financial Metrics and Capital Structure
The filing does not provide revenue, profit, cash flow, or debt metrics. Financial data is limited to capital structure and option valuation:
- Issued and Outstanding Capital: 135,097,367 Ordinary Shares.
- Fully Diluted Capital: 245,360,136 Ordinary Shares (post-grant).
- Option Grant: 3,780,000 unregistered options granted to 14 offerees (2 officers, 12 employees).
- Exercise Price: NIS 0.74607 per option (130% of the 30-day average closing price prior to May 28, 2015).
- Fair Value of Grant: Approximately NIS 1,127,560 total (NIS 2.98 per option) calculated using a binomial model.
- Share Price (TASE): NIS 0.406 as of July 30, 2015.
Material Changes
The primary material change reported is the Board of Directors' approval on May 28, 2015, to grant 3,780,000 new stock options. This grant increases the Company's potential fully diluted share count. The options vest over three years and have a ten-year exercise period. The filing notes that the Company completed its initial public offering in the U.S. on May 15, 2015, with trading commencing on May 12, 2015.
Guidance, Outlook, and Risks
The filing contains no financial guidance, revenue outlook, or management commentary regarding business operations. Key contingencies and risks include:
- Regulatory Approvals: The grant is subject to TASE approval for listing the exercise shares.
- Employment Termination: Options expire immediately if employment is terminated for "Cause" (e.g., moral turpitude, embezzlement, breach of fiduciary duty). In cases of retirement or termination without cause, vested options may be exercised for 90 days.
- Tax Liability: Offerees bear all tax duties and mandatory payments; the Company will deduct taxes at source as required by law.
- Valuation Risk: The fair value calculation assumes a standard deviation of 87% and a risk-free rate of 2.0%.
Investor Verification Checklist
- Verify the final approval status of the option grant by the Tel Aviv Stock Exchange (TASE).
- Confirm the impact of the 3,780,000 new options on the fully diluted share count and potential dilution to existing shareholders.
- Review the Company's Periodic Report for 2014 and Q1 2015 report for actual revenue and cash flow data, as this filing does not contain them.
- Monitor the Company's cash position to ensure it can support operations, given the lack of reported revenue in this filing.
- Check for any subsequent immediate reports regarding the exercise of these options or changes in the Compensation Policy.